Systemic therapies for hepatocellular carcinoma.
Tianjin, China. In Drug Discov Ther, Oct 2015
According to the results of SHARP and ORIENTAL study, sorafenib became the standard first-line therapy since 2008 because of nearly three months of survival improvement in patients with advanced HCC.
Practical recommendations for the management of hyperlipidemia.
Dresden, Germany. In Atheroscler Suppl, May 2015
In the SHARP Study the combination of simvastatin plus ezetimibe was effective in reducing cardiovascular events in patients with severe renal insufficiency (especially before dialysis but also in dialysis dependent patients).
Analyses of cancer data from three ezetimibe trials.
Oxford, United Kingdom. In N Engl J Med, 2008
METHODS: We compared the results of a hypothesis-generating analysis of the incidence of cancer in the SEAS trial of ezetimibe plus simvastatin in 1873 patients (mean follow-up after ezetimibe or matching placebo was begun, 4.1 years) with a hypothesis-testing analysis of cancer data from the two large ongoing trials of this regimen: the Study of Heart and Renal Protection (SHARP) (NCT00125593) with 9264 patients (mean follow-up, 2.7 years) and the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) (NCT00202878), currently with 11,353 patients (mean follow-up, 1.0 year).
Regulation of lymphocyte development by Notch signaling.
Moriyama, Japan. In Nat Immunol, 2007
Here we highlight parallels in the developmental regulation of mammalian lymphocytes and the D. melanogaster nervous system through Notch cooperation with the transcriptional regulators RBP-J (Su(H)), MINT (Hairless) and E2A (Ac-Sc-Da).